Industrial Pharmacy Advisory Group (IPAG)

Experts in Industrial Pharmacy

RPS Industrial Pharmacy Advisory Group (IPAG) provides a source of expertise on issues of pharmacy practice which impact on patients, the public, and the profession.

IPAG is a consultative group to the Boards of the RPS, acting as a source of expertise and advice, and providing evidenced-based leadership and opinion to inform RPS policy decisions and advice to government and other organisations.

The main aim of IPAG is to provide leadership in practice, identify and track the changing healthcare environment, advise on the implications for the industrial sector and the RPS and also highlight the changing professional needs and competencies of its members.

Read the Terms of Reference for the Industrial Pharmacy Advisory Group (IPAG).

Members

Sunayana Shah (Chair)

  • Neel Bhatt
  • Ciara O'Brien
  • Jeremy Clarke
  • Vito Constanza
  • Diar Fattah
  • Sarah Goffin
  • Hari Harrar
  • Pervaise Khan
  • Sue Kilby
  • Yetunde Kolade
  • Jenifer Mains
  • Stephen Makin
  • Ricardo Martinez-Moreno-Davila
  • Jane Nicholson
  • Mine Orlu
  • Marco Picone
  • Kendall Pitt
  • Robert Smith
  • Rebecca Stanbrook
  • Pratik Thakkar  

IPEAG flyer for 31 May webinarEIPG May Webinar

Pharmacovigilance as a specialisation, and the role of the Pharmacovigilance Risk Assessment Committee (PRAC)

With Sofia Trantza

Click the flyer to download a copy.

Wednesday, 31 May 2023, 1700 CEST (1600 GMT)

CLICK HERE TO REGISTER

EPIG June webinar flyerEIPG June Webinar

The Interface between Pharmaceutical Products and Medical Devices from a Product Development perspective

With Janet Halliday

Click the flyer to download a copy.

Monday, 26 June 2023, 1700 CEST (1600 GMT)

CLICK HERE TO REGISTER

The EIPG newsletter

Read the official newsletter of the European Industrial Pharmacists' Group.

  • Read the February 2023 newsletter
    In this February issue, you'll find news about The Windsor Framework, a Review of the pharmaceutical legislation, the proposals of the industrial associations, an EMA/EFSA joint report on human dietary exposure to residues of veterinary medicines, pesticides and feed additives, and HERA reports on stockpiling of antimicrobials.
  • Read the October 2022 newsletter
    In this October issue, you'll find articles on Drug substance supply in new product introduction processes, MDCG, a position paper on the capacity of notified bodies, the current status of trade agreements, and a warning from the FDA about manufacturing on the same equipment.
  • Read the September 2022 newsletter
    In this September issue, you'll find articles on ACT EU’s Workplan 2022-2026, Real-world evidence for regulatory decision-making, EFPIA’s Annual Report on the Pharmaceutical industry 2022, and Patient involvement in the development, regulation and safe use of medicines.
  • Read the July 2022 newsletter
    In this July issue, you'll find articles on the EMA's industry stakeholders' group (or ISG), ICMRA - two pilot programmes to optimise regulatory assessment and inspections, the new European innovation agenda, and Trends in Drug delivery and Formulation.
  • Read the June 2022 newsletter
    In this June issue, you'll find articles on IVD regulation in force & new MDCG guidelines (CTR –UDI), The Digital Application Dataset Integration (DADI) user interface, EIC: challenges for the governance & opportunities for innovation, The Data Governance Act & the protection of personal data (CTIS) and Consultation on draft Q&As on remote certification of batches.
  • Read the May 2022 newsletter
    In this May issue, you'll find articles on Key issues in technical due diligences, Joint implementation plan for the IVDR regulation, Draft topics for the first IHI calls for proposals, The PIC/S Annual Report 2021 and Implications and Opportunities of ICHQ2(R2) and ICHQ14.